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tween recumbent and standing blood pressures was 5
mmHg. The mean rise in blood urea after therapy was
only 4 mg/ 100 ml. Ten patients suffered from renal hyper-
tension, and there was no deleterious effect on therapy.
This clinical trial showed that the combination of
methyldopa and prindolol is of value in the treatment of
severe hypertension. Previous work has shown the value
of combining propranolol with hydralazine,'· prindolol with
a diuretic' or hydralazine: It is possible that the combi-
nation of methyldopa with the newer ,a-adrenergic blocking
agents may be a suitable alternative to the sympatholitic
agents in the treatment of severe hypertension.
I wish to thank Sandoz Pharmaceuticals (SA) Ltd for their
support.
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A Double-Blind Gastroscopic Study of a
Bismuth-Peptide Complex in Gastric Ulceration
M. G. MOSHAL
SUMMARY
Forty courses of treatment with bicitropeptide (BCP)
were administered to 30 patients with gastric ulcers, in
a double-blind crossover trial. Healing was judged gastro-
scopically after 4 weeks, at which time 79% of ulcers had
healed on BCP and 35% on placebo (P<O,Ol). There
were no side-effects. Bicitropeptide is a bismuth-protein
complex, active at a pH of less than 4. A protective
'protein-bismuth complex' layer is said to be formed over
the ulcer.
S. AII'. Med. l., 48, 1610 (1974).
At present the only treatments that have been shown in
controlled trials to affect the rate of healing of gastric
ulcers are carbenoxolone sodium.' bed rest and cessation
of smoking.' The drug carbenoxolone sodium causes
the advent of side-effect, in a small but significant number
of patients, including salt and water retention. Symptoms
may be relieved by antacids," but these appear not to
affect the rate of healing. In this trial, the effect of a
bismuth-protein complex (bicitropeptide (BCP); Med-Nim)
active at the range of acid pH (below 4,0) usually present
in the stomach, has been tested in the treatment of gastric
ulceration.
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METHODS
Thirty patients with benign chronic gastric ulceration seen
on endoscopy were studied. Only patients with solitary
ulcers on the lesser curve of the stomach in the neigh-
bourhood of the angulus were studied. Each patient had
a pretreatment barium meal, gastric acid output measured
after pentagastrin: in the test modified after Kay," and
a gastroscopy. The gastroscope employed was the side-
view Olympus GF type B, which has an automatic 16-mm
camera. All patients were ambulant and were given
treatment with BCP or placebo in a double-blind fashion
at a dose of 10 ml in 30 ml of water 4 times daily, half
an hour before meals and on retiring at night, for 4
weeks. Crossover was effected if symptoms had not abated
within 2 weeks. Clinical assessment was made every 2
weeks, and gastroscopic assessment was made after 4
weeks of treatment. No patient was admitted to the trial
if there was a complication such as haematemesis or
pyloric obstruction, or if there was coexisting duodenal
ulceration. Patients were advised to avoid only those
foods which appeared to produce symptoms. Smoking was
not discussed, no sedatives or other drugs were given, and
no change in resting habits was advised.
RESULTS
Forty courses of treatment were given to the 30 patients
(Table I). Ten patients received crossover therapy (7 of
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TABLE I. EFFECT OF BICITROPEPTlDE ON THE GASTROSCOPIC HEALING OF GASTRIC ULCERS AT 4 WEEKS
Healed Not healed
Age of patients Length of history
(yrs) (weeks)
Male Female Male Female
No. of No. of
patients No. M SO No. M SO No. M SO No. M SO patients
Bicitropeptide 19* (79%) 14 45,7 10,0 5 41,4 11,1 14 12,0 13,7 5 12,7 13,1 5
Placebo 6 (35%) 4 35,5 9,0 2 46,0 3,0 4 11,0 8,1 2 9,0 7,0 10
• x' = 7.112; P<0.01.
the la placebo failures were placed on BCP and sub-
sequently healed; and 3 of the 5 BCP failures were placed
on placebo and subsequently healed). As seen on gastro-
scopy and barium meal, at 4 weeks after onset of
treatment, 19 gastric ulcers (79%) had healed on BCP.
The time taken for disappearance of symptoms
was 6,2 ± 3,8 days (mean ± SD). The ulcers of 5 patients
did not heal completely on BCP on gastroscopy, although
3 of these had a partial respon~e both clinically and on
gastroscopy. The ulcers of 6 patients healed on placebo
(35?o). The mean time for disappearance of symptoms in
the 6 patients whose ulcers healed on placebo was 9,5 ±
4,2 days. The ulcers of 10 patients failed to heal on
placebo. A x' of 7,112 was obtained in favour of BCP,
which is significant at the P<O,OI level. The ages of the
patients in each treatment group, and the mean length
of history are shown in Table I. There were similarities
in each group in age and length of history. All patients
secreted acid (maximal acid output, mEqjh: males (mean
± SD) 17,9 ± 7,8; range 1,8 to 28,1; females (mean
± SD) 12,7 ± 6,2; range 0,8 to 21,3).
DISCUSSION
Bicitropeptide is a stabilised solution of soluble
bismuth-proteinate complexes. The carrier proteins (pep-
tides) appear to play an important role. These peptides
allow bismuth to be liberated and exchanged with tissue
protein over the range of acid pH values normally
encountered in the stomach. The bismuth is then selec-
10
tively transferred to the actively growing wound tissue
in the ulcer. A protective 'protein-bismuth complex' layer
is formed over the ulcer site, protecTIng it from the acid
pepsin action of gastric juice, enabling healing of the
ulcer to occur." Trapped pepsin may be inactivated in the
bismuth section of the protective layer.' Hecause BCP
insulates the ulcer from the harmful acid-pepsin digestion,
no concomitant therapy is indicated, such as special diets
or antacids. Assays for bismuth in blood and organs of
animals, and in blood and urine of humans following
ingestion of BCP have failed to reveal detectable- amounts
of bismuth in dilutions of 3 parts per million: No
acute toxic or teratogenic effects have been observed in
animals." BCP compound has been shown to provide
effective therapy in ambulant patients with gastric and
duodenal ulcers""
The present double-blind trial has demonstrated that
in patients on BCP, 79% of gastric ulcers healed.
In patients on placebo only 35% of ulcers healed. This is
a significant result in favour of BCP (x' 7,112, P<O,OI).
No side-effects were observed in this trial, and in this
respect BCP has an advantage compared with antacids,
anticholinergics or carbenoxolone sodium.
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